The Scandinavian Propaten® Trial – 1-Year Patency of PTFE Vascular Prostheses with Heparin-Bonded Luminal Surfaces Compared to Ordinary Pure PTFE Vascular Prostheses – A Randomised Clinical Controlled Multi-centre Trial  by Lindholt, J.S. et al.
F
A
t
D
E
t
g
i
w
w
f
c
a
c
i
t
d
u
(
w
b
s
g
f
t
E
T
e
v
g
g
(
V
m
v
(
(
0
q
1
w
l
(
u
r
f
(
c
JOURNAL OF VASCULAR SURGERY
Volume 53, Number 5 Abstracts 1451attractive treatment method for vascular infections of the abdominal aorta.
Still, more follow-up is needed to evaluate long-term results.
Pharmacological Interventions to Attenuate the Expansion of Abdom-
inal Aortic Aneurysm (AAA) – A Systematic Review
Bergqvist D. Eur J Vasc Endovasc Surg 2011;41:663-7.
Introduction: Is it possible by pharmacological methods to attenuate
the expansion rate of abdominal aortic aneurysms?
Method: An Internet-based systematic literature search was performed
to identify published reports on pharmacological methods to influence
aneurysmal expansion rate.
Results: Of an original 450 articles, 22 remained to review: they
included 15 cohort studies with 12,321 patients and seven randomised
clinical trials (RCTs) with 1546 patients. Most studies are performed with-
out a pre-study sample size calculation. There is no consistent pattern of
pharmacological influence on expansion rate, but statins, non-steroidal
anti-inflammatory drugs (NSAIDs) and macrolides should be further eval-
uated.
Conclusion: Properly designed RCTs are needed before conclusions
can be drawn on the possibility to pharmacologically attenuate aneurysmal
expansion and prevent rupture.
The Scandinavian Propaten® Trial – 1-Year Patency of PTFE Vascular
Prostheses with Heparin-Bonded Luminal Surfaces Compared to Or-
dinary Pure PTFE Vascular Prostheses – A Randomised Clinical Con-
trolled Multi-centre Trial
Lindholt J.S., Gottschalksen B., Johannesen N., Dueholm D., Ravn H.,
Christensen E.D., Viddal B., Flørenes T., Pedersen G., Rasmussen M.,
Carstensen M., Grøndal N., Fasting H. Eur J Vasc Endovasc Surg 2011;41:
668-73.
Objective: To compare 1-year potencies’ of heparin-bonded PTFE
[(Hb-PTFE) (Propaten®)] grafts with those of ordinary polytetraflouroeth-
ylene (PTFE) grafts in a blinded, randomised, clinically controlled, multi-
centre study.
Materials and methods: Eleven Scandinavian centres enrolled 569
patients with chronic functional or critical lower limb ischaemia who were
scheduled to undergo femoro–femoral bypass or femoro–poplitaeal bypass.
The patients were randomised 1:1 stratified by centre. Patency was assessed
by duplex ultrasound scanning. A total of 546 patients (96%) completed the
study with adequate follow-up.
Results: Perioperative bleeding was, on average, 370 ml with PTFE
grafts and 399 ml with Heparin-bonded PTFE grafts (p  0.32).
Overall, primary patency after 1 year was 86.4% for Hb-PTFE grafts
and 79.9% for PTFE grafts (OR 0.627, 95% CI: 0.398; 0.989, p 0.043).
Secondary patency was 88% in Hb-PTFE grafts and 81% in PTFE grafts
(OR  0.569 (0.353; 0.917, p  0.020)).
Subgroup analyses revealed that significant reduction in risk (50%) was
observed when Hb-PTFE was used for femoro–poplitaeal bypass (OR 
0.515 (0.281; 0.944, p  0.030)), and a significant reduction in risk (50%)
was observed with Hb-PTFE in cases with critical ischaemia (OR  0.490
(0.249; 0.962, p  0.036)).
Conclusion: The Hb-PTFE graft significantly reduced the overall riskReaders can access EJVES articles at http://intl.eive-year Results of a Randomised Clinical Trial of Endovenous Laser
blation of the Great Saphenous Vein with and without Ligation of
he Saphenofemoral Junction
isselhoff B.C.V.M., der Kinderen D.J., Kelder J.C., Moll F.L. Eur J Vasc
ndovasc Surg 2011;41:685-90.
Objective: To evaluate whether ligation of the saphenofemoral junc-
ion (SFL) improves the results of endovenous laser ablation (EVLA) of the
reat saphenous vein (GSV) in a 5-year randomised clinical trial (RCT).
Methods: Forty-three symptomatic patients (86 limbs) with bilateral
ncompetent GSVs were randomised so that one limb underwent EVLA
ithout SFL and the other limb underwent EVLA with SFL. Eleven patients
ere lost to follow-up and two patients died, leaving 30 patients (60 limbs)
or analysis. Duplex-confirmed groin varicose vein recurrence and venous
linical severity score (VCSS) were investigated at 6, 12, 24 and 60 months
fter treatment.
Results: Five-year life table analysis showed freedom from groin vari-
ose vein recurrence in 79% of limbs (95% confidence interval (CI); 67–92%)
n the EVLA without SFL group and in 65% of limbs (95%; CI; 51–82) in
he EVLA with SFL group (P  0.36). Groin varicose vein recurrence was
ue to neo-vascularisation (0%), re-canalisation (9%) and incompetent trib-
taries in 14% in the EVLA without SFL group, and to neo-vascularisation
33%), re-canalisation (0%) and incompetent tributaries (0%) in the EVLA
ith SFL group. The VCSS improved significantly and was comparable in
oth groups.
Conclusion: The rate of varicose vein recurrence was similar in both
tudy groups. There was less neo-vascularisation in the EVLA without SFL
roup, but more incompetent tributaries and early re-canalisation at 5-year
ollow-up than in the EVLA with SFL group.
Registration number: ISRCTN60300873 (http://www.clinical-
rials.com).
ndovenous Laser Ablation (EVLA) to Treat Recurrent Varicose Veins
heivacumar N.S., Gough M.J. Eur J Vasc Endovasc Surg 2011;41:691-6.
Objectives: This cohort study assesses the effectiveness and safety of
ndovenous laser ablation (EVLA) in the management of recurrent varicose
eins (RVVS).
Method: 104 limbs (95 patients) undergoing EVLA for RVVS were
rouped according to pattern of reflux. For patients with recurrent SFJ/
reat saphenous vein (GSV) (Group GR) and SPJ/small saphenous vein
SSV) (Group SR) varicosities ablation rates and QoL (Aberdeen Varicose
ein Severity Scores (AVVSS)) were compared with those for age/sex
atched patients undergoing EVLA for primary GSV/SSV dependent
aricose veins (Groups GP and SP).
Results: In patients with RVVS the axial vein was ablated in 102/104
98%) limbs whilst 2 GSVs (group GR) partially recanalised by 3 months
GSV ablated in 49/51 (96%) limbs versus 50/51 (98%) limbs in GP [p 
.2]). Improvements in AVVSS at 3 months (median GR: 14.2 (inter-
uartile range (IQR) 10.2–18.9) to 3.2(1.2–6.4), p  0.001; GP: median
5.9(IQR 11.4–22.7) to 3.8(1.1–5.6), p  0.001, Mann–Whitney u-test)
ere similar (78% versus 76%, p  0.23). The SSV was ablated in 24/24
imbs in groups SR and SP and the % improvement in AVVSS was 83%
median 14.4 (IQR 8.2–19.4) to 2.4 (1.9–4.6), p 0.001, Mann–Whitney
-test) and 84% (median 13.8 (IQR 6.3–17.5) to 2.2 (1.2–5.1), p 0.001)
espectively (p 0.33). These improvements persisted at 1 year follow-up. A
urther 29 limbs with isolated anterior accessory great saphenous vein
AAGSV) or segmental GSV/SSV reflux were successfully ablated. Compli-
ation rates for primary and RVVS were similar.of primary graft failure by 37%. Risk reduction was 50% in femoro–poplitaeal
bypass cases and in cases with critical ischaemia.
Conclusions: EVLA is a safe and effective option for the treatment of
RVVS and could be a preferred option for suitable patients.lsevierhealth.com/journals/ejvs/default.cfm
